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Abstract
Background: Long QT syndrome type 2 (LQT2) is the second most common type of all long QT syndromes. It is well-known
that trafficking deficient mutant human ether-a-go-go-related gene (hERG) proteins are often involved in LQT2. Cells respond
to misfolded and trafficking-deficient proteins by eliciting the unfolded protein response (UPR) and Activating Transcription
Factor (ATF6) has been identified as a key regulator of the mammalian UPR. In this study, we investigated the role of ER
chaperone proteins (Calnexin and Calreticulin) in the processing of G572R-hERG and E637K-hERG mutant proteins.
Methods: pcDNA3-WT-hERG, pcDNA3-G572R-hERG and pcDNA3-E637K-hERG plasmids were transfected into U2OS and
HEK293 cells. Confocal microscopy and western blotting were used to analyze subcellular localization and protein expression.
Interaction between WT or mutant hERGs and Calnexin/Calreticulin was tested by coimmunoprecipitation. To assess the role
of the ubiquitin proteasome pathway in the degradation of mutant hERG proteins, transfected HEK293 cells were treated with
proteasome inhibitors and their effects on the steady state protein levels of WT and mutant hERGs were examined.
Conclusion: Our results showed that levels of core-glycosylated immature forms of G572R-hERG and E637K-hERG in
association with Calnexin and Calreticulin were higher than that in WT-hERG. Both mutant hERG proteins could activate the
UPR by upregulating levels of active ATF6. Furthermore, proteasome inhibition increased the levels of core-glycosylated
immature forms of WT and mutant hERGs. In addition, interaction between mutant hERGs and Calnexin/Calreticulin was
stronger after proteasome inhibition, compared to WT-hERG. These results suggest that trafficking-deficient G572R-hERG
and E637K-hERG mutant proteins can activate ER stress pathways and are targeted to the proteasome for degradation.
Calnexin and Calreticulin play important roles in these processes.
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Introduction
Congenital long QT (LQT) syndrome is a heterogeneous
genetic disease and LQT type 2 (LQT2) is the second most
common type. It is characterized by delayed ventricular
repolarization, QT prolongation on ECG, development of
ventricular arrhythmias (torsades de pointes) and sudden deaths,
particularly in children and teenagers [1–3]. To date, twelve genes
have been identified to be responsible for LQT syndrome [4–6].
The human ether-a-go-go-related gene (hERG, also known as
KCNH2) gene encodes the Kv11.1 protein a-subunit, which
assembles into a voltage-gated K channel on plasma membrane
and underlies the rapidly activating delayed rectifier K-current
(IKr) in the heart [7]. Mutations in hERG channels have been
implicated in the pathophysiology of LQT2 [8,9]. To date,
approximately 300 hERG mutations have been identified in
LQT2 patients [10–12]. The most common mechanism of hERG
channel dysfunction in these patients is defective protein-
trafficking resulting in retention in the endoplasmic reticulum
(ER) and failure to reach the plasma membrane [13].
Cells respond to the expression of misfolded and trafficking-
deficient transmembrane proteins by eliciting the unfolded protein
response (UPR), an ER stress pathway that increases the synthesis
of chaperones proteins [14,15]. UPR consists of both translational
and transcriptional regulations. Activating Transcription Factor 6
(ATF6) has been identified as a key regulator of transcriptional
control in the mammalian UPR [16]. Specifically, UPR activates
the cleavage of ATF6 into its activated form, which then
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Molecular chaperones play important roles in the biogenesis and
quality control of many proteins, including glycoproteins [18,19].
Calnexin and Calreticulin are two key chaperone proteins in the
ER responsible for ensuring the proper folding of newly syn-
thesized proteins, as well as other quality control mechanisms
[14,15]. Misfolded and trafficking-deficient proteins retained in
the ER are eventually degraded by a process termed ER-
associated degradation (ERAD). According to current models,
ERAD substrates undergo retro-translocation or dislocation from
the ER to the cytosol, where they are degraded by the ubi-
quitination-proteasome pathway [18].
Although hERG channels have been studied extensively, little is
known about the exact mechanism underlying the maturation and
processing of trafficking-deficient hERG mutant proteins. G572R-
hERG and E637K-hERG are two mutant forms of the hERG
channel that have been previously reported as trafficking-deficient
[20,21]. However, the exact process by which they are retained in
the ER is not well understood. In the present study, we evaluated
the role of Calnexin/Calreticulin in the processing of trafficking-
deficient G572R-hERG and E637K-hERG mutant proteins.
Specifically, we studied whether the ER stress pathway is involved
and whether the mutant proteins are degraded by ubiquitin-
mediated proteasome. Our results suggest that trafficking-deficient
G572R-hERG and E637K-hERG mutant proteins can activate
UPR and are targeted to the proteasome for degradation.
Furthermore, the interaction between mutant hERG proteins
and chaperone proteins, Calnexin and Calreticulin, play crucial
roles in these processes.
Methods
cDNA cloning and cell culture
The WT-hERG was cloned into pcDNA3 vector (Invitrogen;
Carlsbad, CA) as described previously [22]. G572R-hERG and
E637K-hERG mutants were generated by site-directed mutagen-
esis and subcloned into pcDNA3 vector at BstEII/XhoI restriction
sites. These constructs were introduced into HEK293 and U2OS
cells through transient transfection using Lipofectamine
TM 2000 as
described by the manufacturer (Invitrogen). Transfection efficien-
cy was estimated to be approximately 90%. HEK293 and U2OS
cells were cultured in Dulbecco’s modified Eagle’s medium,
supplemented with 10% fetal bovine serum, maintained in a
humidified 5% CO2 incubator at 37uC. Cells were not used
beyond 30 passages.
Western blotting analysis
HEK293 cells expressing WT and mutant hERGs in 100-mm-
diameter culture dishes were harvested 48 hours after transfection.
Proteins were separated on SDS polyacrylamide gels and then
transferred to polyvinylidene difluoride membranes (Pierce
Biotechnology, USA). Primary antibodies used included rabbit
polyclonal anti-hERG (Alomone Labs, Israel), rabbit polyclonal
anti-ATF6 (Active Motif, USA), mouse monoclonal anti-Calnexin
(Santa Cruz Biotechnologies, USA) and anti-Calreticulin (Abcam,
USA). Blots were visualized with SuperSignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology, USA) and
developed using Syngene Chemi-Genius imaging system (Syn-
Gene, UK).
Immunofluorescence and confocal imaging
U2OS cells seeded on coverslip in 6-well plate were transiently
transfected with pcDNA3-WT-hERG, pcDNA3-G572R-hERG or
pcDNA3-E637K-hERG plasmid. At 48 hours post-transfection,
cells were fixed with paraformaldehyde, permeabilized with 0.1%
Triton X-100 and blocked with 5% goat serum at room
temperature (RT). Cells were then labeled with rabbit polyclonal
anti-hERG (1:25 dilution) and mouse monoclonal anti-Calnexin
or anti-Calreticulin (1:25 dilution) at 4uC overnight, followed by
incubation with FITC-conjugated goat anti-rabbit IgG secondary
antibody and TRITC-conjugated goat anti-mouse IgG secondary
antibody at RT for 2 hours. Signals were captured with a Leica
TCS SP2 confocal laser scanning microscope.
Coimmunoprecipitation
HEK293 cells were transiently transfected with pcDNA3-WT-
hERG, pcDNA3-G572R-hERG or pcDNA3-E637K-hERG plas-
mid and then lysed in 500 ml of immunoprecipitation buffer
(50 mM Tris-HCl, pH 8.0, containing 150 mM NaCl, 1 mM
CaCl2, and 1% Triton X-100) with protease inhibitors (100 mM
PMSF, 1 mg/ml pepstatin A, 1 mg/ml leupeptin, 4 ml/ml
aprotinin). Cell lysates were pre-cleared by incubation with
protein G plus-agarose beads (Santa Cruz Biotechnologies, USA)
and incubated with 3 mg of antibody against Calnexin or
Calreticulin at 4 uC overnight. The antigen-antibody complexes
were isolated with protein G plus-agarose beads and washed with
the immunoprecipitation buffer. The bound antigens were eluted
from the protein G plus-agarose beads by 26sample buffer and
analyzed by immunoblotting with anti-hERG, anti-Calnexin and
anti-Calreticulin antibodies.
Proteasome inhibitor studies
Transiently transfected HEK293 cells were treated with 20 mM
lactacystin, 50 mM ALLN or 100 mM leupeptin for 24 hours. Part
of the cell lysates were immunoblotted with anti-hERG, anti-
Calnexin and anti-Calreticulin antibodies. The remaining lysates
were immunoprecipitated with anti-ubiquitin (Santa Cruz Bio-
technologies, USA), anti-hERG, anti-Calnexin or anti-Calreticulin
antibodies.
Cycloheximide chase experiments
HEK293 cells were transiently transfected with G572R-hERG
and E637K-hERG plasmids. At 24-hrs post- transfection, cells
were treated with 100 mg/ml of cycloheximide and harvested at 0,
4, 8, and 12 hr post-treatment.
Results
G572R-hERG and E637K-hERG mutants co-localize with
Calnexin/Calreticulin in the ER and they result in protein
trafficking deficiency
The subcellular localization and protein trafficking of WT-
hERG, G572R-hERG and E637K-hERG proteins were exam-
ined by immunostaining and confocal imaging (Fig. 1). U2OS
cells transfected with pcDNA3-WT-hERG, pcDNA3-G572R-
hERG and pcDNA3-E637K-hERG plasmids were co-stained
with hERG antibody (green; the first and fourth columns) and
ER marker proteins - Calnexin antibody (red; the second column)
and Calreticulin antibody (red, the fifth column). The confocal
images clearly demonstrate that WT-hERG protein is expressed
both on the cell surface (arrow) and within the cytoplasm. In
contrast, G572R-hERG and E637K-hERG proteins are mainly
expressed in the cytoplasm. Specifically, the mutant hERG
proteins are retained in the ER with Calnexin and Calreticulin,
as suggested by the uniform yellow color in the merged images
(the third and sixth columns). Therefore, we conclude that
Calnexin/Calreticulin co-localize with G572R-hERG and
E637K-hERG proteins in the ER.
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type and mutant hERG proteins, HEK293 cells were transiently
transfected with pcDNA3-WT-hERG, pcDNA3-G572R-hERG or
pcDNA3-E637K-hERG plasmid and analyzed by Western blot.
In Figure 2, WT-hERG transfected cells (first lane) show two
protein bands with the upper band at 155 kDa representing the
fully-glycosylated, mature form of the protein transported to the
cell membrane surface. The lower band at 135 kDa represents the
core-glycosylated, immature form of the protein localized to the
ER. In contrast, G572R-hERG and E637K-hERG transfected
cells (second and third lanes) express only the immature form of
the protein at 135 kDa but no fully-glycosylated form of the
protein of 155 kDa. These data suggest that the G572R-hERG
and E637K-hERG mutant proteins are trafficking-deficient such
that only the core-glycosylated, immature form of the protein is
expressed.
Calnexin/Calreticulin interact with core-glycosylated
forms of WT-hERG, G572R-hERG and E637K-hERG
To assess the physical interaction between hERG and
Calnexin/Calreticulin, immunoprecipitation was done with anti-
Calnexin or anti-Calreticulin antibody, followed by Western blot
Figure 1. Confocal imaging of WT-hERG and G572R-hERG/E637K-hERG channels in U2OS cells. U2OS cells were transfected with WT-
hERG, G572R-hERG and E637K-hERG plasmids and co-stained with anti-hERG (green) and anti-Calnexin or anti-Calreticulin (red) antibodies, as
indicated. Calnexin and Calreticulin localize to the ER (top row) while WT-hERG (second row) localizes to both plasma membrane (indicated by white
arrows) and cytoplasm. G572R-hERG (third row) and E637K-hERG (bottom row) mutants localize exclusively to the ER, as shown by the overlap with
ER markers (Calnexin and Calreticulin) (scale bar 5 mm).
doi:10.1371/journal.pone.0029885.g001
Figure 2. Analysis of WT-hERG, G572R-hERG and E637K-hERG
protein expressions in HEK293 cells. Lysates from HEK293 cells
expressing WT-hERG, G572R-hERG or E637K-hERG were immunoblotted
with anti-hERG antibody. Only WT-hERG expressing cells have both the
fully-glycosylated, mature form and core-glycosylated, immature form
of the hERG protein. Both G572R-hERG and E637K-hERG expressing cells
only have the core-gylcosylated, immature forms of the hERG protein.
doi:10.1371/journal.pone.0029885.g002
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core-glycosylated, immature forms of WT-hERG, G572R-hERG
and E637K-hERG all interact with Calnexin/Calreticulin while
the fully-glycosylated, mature forms of hERG proteins do not.
Moreover, the proportion of G572R-hERG or E637K-hERG
associated with Calnexin/Calreticulin is greater in comparison
with WT-hERG, indicating that G572R-hERG and E637K-
hERG have prolonged associations with Calnexin/Calreticulin.
G572R-hERG and E637K-hERG activate ER stress
responses via activation of ATF6
Since Calnexin/Calreticulin are chaperone proteins with
important regulatory roles in the ER quality control pathways,
we want to test whether the trafficking-deficient G572R-hERG
and E637K-hERG mutants can activate ER stress responses.
Given that ATF6 has been identified as a key regulator of
transcriptional control during the mammalian UPR, HEK293
cells were transfected with wild-type and mutant hERG protein
plasmids and ATF6 protein expression was analyzed by Western
blot. The cells were harvested and lysed at 48-hrs post-
transfection. As shown in Figure 4, WT-hERG, G572R-hERG
and E637K-hERG expressing cells all have an upper band at
90 kDa, which represents the unprocessed ATF6 embedded in
ER. However, only G572R-hERG and E637K-hERG expressing
cells (second and third lanes) have a lower band at 50 kDa, which
represents the cleaved form of ATF6 capable of activating
transcription of ER stress response genes. These results indicate
that expression of G572R-hERG and E637K-hERG mutants
result in accumulation of folding-deficient proteins in the ER,
which in turn elicits the UPR, as demonstrated by activation of
ATF6.
Mutant hERG channels are degraded through ubiquitin-
mediated proteasome pathway
To assess the involvement of proteasome-mediated degrada-
tion of hERG proteins, we examined the effects of proteasome
inhibitors (lactacystin and ALLN) on the steady state protein
levels of WT-hERG, G572R-hERG and E637K-hERG. As
shown in Figure 5a, treatment with lactacystin or ALLN but
not leupeptin (a lysosome inhibitor) results in an increase in the
levels of core-glycosylated, immature form of hERG, Calnexin
and Calreticulin. To further validate that the immature forms
of wild-type and mutant hERG proteins are degraded through
the ubiquitination-mediated proteasome pathway, transiently
transfected HEK293 cells were treated with lactacystin, ALLN
or leupeptin and lysates were subjected to immunoprecipitation
with anti-hERG antibody. Precipitates were then immuno-
blotted with antibody against poly-ubiquitinated proteins. We
found that proteasome inhibition increases levels of hERG
poly-ubiquitination and to a greater extent for G572R-hERG
or E637K-hERG than WT-hERG (Fig. 5b). However,
treatment with leupeptin had no effect at all on hERG poly-
ubiquitination. Next, we proceeded to examine the rate of
hERG mutant degradation. Protein translation in G572R-
hERG and E637K-hERG expressing cells was inhibited by
cycloheximide treatment and hERG protein levels were
analyzed at the indicated time points. As shown in Figure 5c,
protein levels of both G572R-hERG and E637K-hERG
mutants are decreased after cycloheximide treatment with
half-life less than 6 hrs.
To further examine the role of proteasome in the degradation of
hERG proteins, coimmunoprecipitation analysis was performed.
Similarly, transiently transfected HEK293 cells were treated with
lactacystin or ALLN and cells were harvested at 24-hours post-
treatment. The cell lysates were then immunoprecipitated with
anti-Calnexin or anti-Calreticulin antibody and the precipitates
were immunoblotted with anti-hERG antibody. As shown in
Figure 6, the interaction between Calnexin/Calreticulin and
hERG mutant proteins has increased significantly after lactacystin
and ALLN treatment. However, proteasome inhibitor treatment
has a much weaker effect on the association of Calnexin/
Calreticulin with the immature form of hERG protein in WT-
hERG expressing cells, as shown in Figure 6. Furthermore, there
was no interaction between the mature form of hERG protein and
Calnexin/Calreticulin.
Discussion
Previous studies have shown that misfolded, incompletely folded
and unassembled proteins are retained in the ER. This process is
under stringent surveillance by the ER quality control system,
which involves molecular chaperones that transiently associate
with newly synthesized proteins to promote their proper folding
and assembly [13,19]. Misfolded and unassembled proteins
Figure 3. Association of hERG channels with Calnexin and
Calreticulin. Lysates from HEK293 cells expressing WT-hERG, G572R-
hERG and E637K-hERG were immunoprecipitated with anti-Calnexin
and anti-Calreticulin antibody and immunoblotted with anti-hERG
antibody. The association of Calnexin/Calreticulin with the core-
glycosylated, immature forms of G572R-hERG and E637K-hERG is much
stronger than that with WT-hERG.
doi:10.1371/journal.pone.0029885.g003
Figure 4. Activation of ATF6 by G572R-hERG and E637K-hERG.
HEK293 cells were transfected with WT-hERG, G572R-hERG or E637K-
hERG plasmid. Cell lysates were subjected to Western blotting with anti-
ATF6 antibody. The cleaved, activated form of ATF6 at 50 kDa is only
detected in G572R-hERG and E637K-hERG expressing cells but not in
WT-hERG expressing cells.
doi:10.1371/journal.pone.0029885.g004
hERG Mutants Activate Stress/Clearance Pathways
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cytosol, where they are degraded by the proteasome [18].
Calnexin and Calreticulin are chaperone proteins in the ER that
play important roles in the quality control pathways. G572R-
hERG and E637K-hERG are mutant hERG proteins that have
been previously reported as trafficking-deficient and our current
study seeks to elucidate the mechanism by which they are
processed in the ER [20,21].
Our results show that the trafficking-deficient G572R-hERG
and E637K-hERG mutant proteins are mainly expressed in the
cytoplasm and retained in the ER in association with Calnexin/
Calreticulin. Furthermore, the proportion of Calnexin/Calreti-
culin in association with the core-glycoyslated, immature forms of
G572R-hERG and E637K-hERG mutants is higher than that for
WT-hERG. This indicates that the hERG mutant proteins fail to
fold properly and thereby, accumulate in the ER in prolonged
association with Calnexin/Calreticulin. Similarly, Gong et al has
shown that the N470D-hERG mutant results in protein folding-
deficiency and has prolonged association with Calnexin but not
Calreticulin [23]. It has also been reported that when arginine
vasopressin V2 receptor is mutated, Calnexin has a prolonged
association with it [24]. These results collectively illustrate that
the chaperone complex functions to arrest mutant proteins in the
ER and attempts to re-fold them into the correct native
conformation.
It is well-established that the ER quality control system
operates efficiently such that only correctly folded molecules
can exit the ER while misfolded proteins accumulate in the ER
and activate the UPR [25]. In our current study, baseline
comparison done in HEK293 cells expressing wild-type and
mutant hERG proteins show that the cleaved, activated form of
ATF6 is only detected in G572R-hERG and E637K-hERG
expressing cells but not in WT-hERG expressing cells. This
suggests that an elevated stress response is found in mutant hERG
expressing cells, which is consistent with previous report of ATF6
activation by the I593R-hERG mutant [23]. In turn, activated
ATF6 upregulates expression of chaperone proteins. Ficker et al
has demonstrated the importance of cytosolic chaperones such as
Figure 5. Degradation of G572R-hERG and E637K-hERG mutant channels through ubiquitin-proteasome pathway. a, HEK293 cells
were transfected with WT-hERG, G572R-hERG or E637K-hERG plasmid and then treated with 20 uM lactacystin (LACT), 50 uM ALLN or 100 uM
leupeptin (LEUP) for 24 hours. The cell lysates were subjected to Western blotting with anti-hERG, anti-Calnexin and anti-Calreticulin antibodies.
Proteasome inhibition leads to an increase in the core-glycosylated, immature forms of hERG protein with a more significant increase seen in G572R-
hERG and E637K-hERG expressing cells in comparison with WT-hERG expressing cells. b, Transfected HEK293 cells were treated with proteasome
inhibitors or leupeptin as indicated. Lysates were immunoprecipitated with anti-hERG antibody and immunoblotted with anti-ubiquitin antibody.
Proteasome inhibition results in the accumulation of poly-ubiquitinated G572R-hERG/E637K-hERG and immature WT-hERG (135 kDa). c, Transfected
HEK293 cells were treated with cycloheximide (CHX) and harvested at indicated time points. Lysates were immunoblotted with anti-hERG antibody.
Protein levels of both G572R-hERG and E637K-hERG mutants are decreased after cycloheximide treatment with half-life less than 6 hrs.
doi:10.1371/journal.pone.0029885.g005
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as well as the retention of trafficking-deficient hERG mutants
[26]. Our results show that the mutant hERG proteins
accumulate in the ER and thereby, activate the UPR.
Specifically, expression of G572R-hERG and E637K-hERG
mutant proteins result in an increase in the synthesis of
chaperones proteins via activation of ATF6.
Misfolded proteins retained in the ER are degraded by the
ERAD process, which targets its substrates for ubiquitin-mediated
proteasome degradation pathway. After treatment with protea-
some inhibitors (lactacystin and ALLN), our results show that there
is a notable increase in levels of core-glycosylated, immature forms
of G572R-hERG and E637K-hERG proteins as well as
accumulation of poly-ubiquitinated mutant hERG proteins.
Furthermore, proteasome inhibition increases the association of
Calnexin/Calreticulin with G572R-hERG and E637K-hERG.
Previous study has also shown that lactacystin or ALLN treatment
results in the accumulation of poly-ubiquitinated Y611H-hERG
proteins in the ER and prolonged association with molecular
chaperone compared to WT-hERG [10]. Collectively, these
results strongly suggest that the ubiquitin-mediated proteasome
pathway plays an important role in the ER retention and
degradation of immature forms of G572R-hERG and E637K-
hERG mutant proteins.
In conclusion, our findings provide evidence that the trafficking-
deficient E637K-hERG and G572R-hERG mutants are retained
in the ER and targeted to the proteasome for degradation. In
addition, Calnexin/Calreticulin have prolonged association with
E637K-hERG and G572R-hERG mutant proteins and may
contribute to their degradation. Therefore, elucidating the exact
mechanism by which Calnexin/Calreticulin interact with the
mutant hERG channels will provide further insights into the
pathophysiology underlying LQT2 and also facilitate the search
for new pharmacological methods to restore proper trafficking of
mutant hERG channels.
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